Table 4:
Clinical Efficacy
| Parameter | Outcome |
|---|---|
|
Median Duration of Therapy with: Temsirolimus Bevacizumab |
3.9 months 3.4 months |
| Median Progression-Free Survival | 7.1 months (95% CI 4.6 – 8.7 months) |
| Objective Response Rate | 2% (1 out of 48) |
| Stable Disease Rate | 88% (42 out of 48) |